Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by NPM Pharma Inc.
Sponsor:
Collaborator:
Karyopharm Therapeutics, Inc
Information provided by (Responsible Party):
NPM Pharma Inc.
ClinicalTrials.gov Identifier:
NCT01607892
First received: May 16, 2012
Last updated: April 11, 2014
Last verified: April 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
No publications provided by NPM Pharma Inc.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):